BlossomHill Therapeutics, Inc. Share Price

Stocks

Market Closed - Nasdaq 01:30:00 16/10/2026 am IST			5-day change	1st Jan Change
14.98 ^USD	-1.83%		-11.26%	-

29/09	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
21/09	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI

Market Cap	49Cr 43Cr 40Cr 37Cr 69Cr 4.59TCr 70Cr 483.35Cr 189.12Cr 2.4TCr 182.02Cr 178.16Cr 7.67TCr	P/E 2026 *	-2.78x	P/E 2027 *	-4.62x
Enterprise Value	49Cr 43Cr 40Cr 37Cr 69Cr 4.59TCr 70Cr 483.35Cr 189.12Cr 2.4TCr 182.02Cr 178.16Cr 7.67TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

NasdaqUSD

Markets		Quality
Nasdaq	BLSM	Delayed
CBOE	BLSM	Real-time

29/09	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
21/09	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI
18/09	BlossomHill Therapeutics Q2 Loss Widens	MT
18/09	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT
18/09	BlossomHill Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/09	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 Solara Trial Demonstrating Anti-Tumor Activity of Omni-EGFR Inhibitor BH-30643 in EGFR C797s-Positive NSCLC	CI
15/09	BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial	MT
01/09	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
01/09	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
01/09	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
01/09	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT
18/08	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
18/08	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI

01/09	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
01/09	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
01/09	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
01/09	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT

28/09	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	GL
28/09	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	AQ
18/09	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results	GL
15/09	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer	GL
03/09	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference	GL

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	01/06/2020
Jason Keyes DFI	Director of Finance/CFO	55	01/05/2025
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	01/06/2020
Bihua Chen BRD	Director/Board Member	57	01/02/2021
Yi Shan Li CHM	Chairman	61	01/06/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/08/26	Sundeep Agrawal	Conversion	Director	11,57,048	3.6917%
10/08/26	Cormorant Asset Management LP	Conversion	Company	69,15,568	22.0651%
10/08/26	Vincent Liptak	Buy	General Counsel	47,574	0.1518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	-1.83%	-11.26%	-	-	49Cr
WUXI APPTEC CO., LTD.	+0.21%	-7.67%	+61.07%	+71.32%	6.89TCr
ARGENX SE	+1.66%	-9.54%	+10.39%	+60.04%	5.19TCr
LONZA GROUP AG	+3.14%	+4.61%	+15.36%	+44.42%	4.87TCr
IQVIA HOLDINGS INC.	+3.45%	+4.70%	+33.44%	+36.21%	4.31TCr
REVOLUTION MEDICINES, INC.	-2.20%	+0.61%	+281.88%	+454.69%	4.15TCr
BEONE MEDICINES AG	+6.43%	+6.84%	+18.32%	+115.06%	4TCr
CELLTRION, INC.	+1.28%	-0.76%	+12.67%	+45.10%	3.06TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.21%	-14.22%	+40.33%	-0.94%	2.6TCr
BIONTECH SE	+1.74%	-2.02%	-13.55%	-6.98%	2.23TCr
Average	+1.15%	-4.32%	+51.10%	+90.99%	3.73TCr
Weighted average by Cap.	+1.55%	-3.50%	+54.95%	+97.63%

	2026 *	2027 *
Net sales	-	-
Net income	-10Cr -9.36Cr -8.7Cr -7.91Cr -15Cr -993.14Cr -15Cr -104.49Cr -41Cr -518.17Cr -39Cr -39Cr -1.66TCr	-12Cr -11Cr -10Cr -9.13Cr -17Cr -1.15TCr -17Cr -120.55Cr -47Cr -597.81Cr -45Cr -44Cr -1.91TCr
Net Debt	-	-